|
|
Pham P and Bartlett JG
02-22-2010
-
Available formulation in Zambia: Capsule or tablet: 125 mg; 250 mg.
- Use limited to the treatment of dermatophytic infections of the skin, nails and hair
- Dermatophytes: Griseofulvin 10 mg/kg PO once-daily with fatty meal
- Tinea (nail and scalp): 500 mg PO once-daily x 8weeks (adult); 10mg/kg PO once-daily x 8 weeks (children).
- Take with fatty meals.
- Avoid in pregnancy.
Zambia Information Author: Paul A. Pham, Pharm. D.
- Dermatomycosis
- Tinea capitis, T. corporis, T. pedis, T. unguium, T. cruris and T. barbae
- Tinea corporis/Tinea cruris
- Tinea pedis
- Tinea capitis/Tinea Barbae
- Onychomycosis
brand
name
| generic
| Mfg
| brand
forms
| cost*
|
| Gris-PEG | Griseofulvin ultramicrocrystalline | ~Generic manufacturers | PO
tab
125mg | $1.98 |
|
|
|
| PO
tab
250mg | $2.62 |
| Grifulvin V | Griseofulvin (microcrystalline) | ~Generic manufacturers | PO
tab
500mg | $3.98 |
|
|
|
| PO
susp
125mg/5mL (4oz) | $75.78 |
*Prices represent cost per unit specified and are representative of "Average Wholesale Price" (AWP).
AWP Prices were obtained and gathered by Lakshmi Vasist Pharm D using the Red Book, manufacturer's
information, and the McKesson database.
^Dosage is indicated in mg unless otherwise noted.
- Tineas: 500-1000mg (griseofulvin micronized) once daily or 375-750mg (griseofulvin ultramicronized) once daily x 4-6 weeks.
- Tinea unguium should be treated for at least 4 months.
Usual dose.
Usual dose.
Usual dose.
No data. Usual dose likely.
No data. Usual dose likely.
No data. Usual dose likely.
- GI: nausea, vomiting, diarrhea, flatulence, and heartburn
- Headache
- Angular stomatitis
- Disulfiram-like reaction
- Photosensitivity
- Glossodynia
- Thirst
- Black-furred tongue
- Porphyria
- Hypersensitivity reactions (drug eruption, Erythema multiforme, TEN and Stevens-Johnson syndrome)
- CNS: irritability, confusion, impaired co-ordination, burry vision, and vertigo
- Peripheral neuritis and paresthesias after prolonged therapy
- Interstitial nephritis
- Albuminuria
- Leukopenia and neutropenia
- Hepatitis
- Myositis
- Barbiturates: may decrease griseofulvin concentrations. Monitor for therapeutic response; consider an alternative antifungal.
- Cyclosporin: may decrease serum concentrations. Monitor cyclosporin serum concentrations closely with co-administration.
- Oral contraceptives: may decrease oral contraceptive efficacy. Consider an additional barrier form of contraception.
- Warfarin: may decrease anticoagulation effect. Monitor INR closely with co-administration.
Active against Microsporum, Epidermophyton and Trichophyton spp., but no activity against C. albicans, Cryptococcus neoformans, Aspergillus spp..
Griseofulvin is an older antifungal agent that has been shown to be equivalent to azoles in the treatment of dermatomycosis caused by Microsporum, Epidermophyton and Trichophyton spp. (but not active against C. albicans).
|
|
![Johns Hopkins POC-IT: Point of Care Information Technology [Home]](/images/pocit_logo.gif){kind=logo}
Help
